Enterprise Value
2.808B
Cash
381.8M
Avg Qtr Burn
-82.93M
Short % of Float
12.81%
Insider Ownership
12.61%
Institutional Own.
84.05%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Taldefgrobep alfa (BHV-2000) Details Spinal muscular atrophy | Phase 3 Data readout | |
Troriluzole (BHV-4157) Details Obsessive compulsive disorder | Phase 3 Data readout | |
Troriluzole Details Spinocerebellar Ataxia | Phase 3 Update | |
BHV-1300 Details Rheumatoid arthritis | Phase 1 Data readout |